Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPS Preos Fracture Reduction, Bone Mineral Density Phase III Data To Top Off Late-2004 NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is still seeking a co-promotion partner for the osteoporosis agent. The pivotal study shows significant relative reduction in vertebral fracture risk and change in bone mineral density.

You may also be interested in...



Preos “Approvable” Pending Additional Clinical Data, NPS Says

FDA concerns regarding hypercalcemia and Preos’ injection device call for additional safety information for the osteoporosis therapy.

Preos “Approvable” Pending Additional Clinical Data, NPS Says

FDA concerns regarding hypercalcemia and Preos’ injection device call for additional safety information for the osteoporosis therapy.

NPS Postpones Preos Filing To Add Two-Year Data From PaTH Study

NDA submission for the osteoporosis agent was originally slated for year-end 2004. Firm says two-year results have implications for use of Preos (recombinant parathyroid hormone) with Fosamax (alendronate).

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel